{
    "root": "05c7694a-b215-4a4d-bcd5-8d5a65212640",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamotrigine",
    "value": "20250508",
    "ingredients": [
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "TRIBASIC CALCIUM PHOSPHATE",
            "code": "91D9GV0Z28"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "BLACK CURRANT",
            "code": "9755T40D11"
        }
    ],
    "indications": "Lamotrigine is indicated for: Epilepsy — adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine in the acute treatment of mood episodes has not been established.",
    "contraindications": "Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. Do not restart lamotrigine in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing products, including oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. ( 2.2 ) Conversion to monotherapy—See Table 4. ( 2.3 ) Bipolar disorder: See Tables 5 and 6. ( 2.4 )",
    "warningsAndPrecautions": "Lamotrigine Tablets\n                  \n                  Lamotrigine Tablets USP, 25 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"79\" and other side is plain and are supplied as follows:\n                  NDC 68382-006-11 in bottles of 25 tablets with child-resistant closure\n                  NDC 68382-006-16 in bottles of 90 tablets with child-resistant closure\n                  NDC 68382-006-01 in bottles of 100 tablets with child-resistant closure\n                  NDC 68382-006-05 in bottles of 500 tablets\n                  NDC 68382-006-10 in bottles of 1000 tablets\n                  Lamotrigine Tablets USP, 50 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"90\" and other side is plain and are supplied as follows:\n                  NDC 68382-007-16 in bottles of 90 tablets with child-resistant closure\n                  NDC 68382-007-01 in bottles of 100 tablets with child-resistant closure\n                  NDC 68382-007-05 in bottles of 500 tablets\n                  NDC 68382-007-10 in bottles of 1000 tablets\n                  Lamotrigine Tablets USP, 100 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"80\"and other side is plain and are supplied as follows:\n                  NDC 68382-008-16 in bottles of 90 tablets with child-resistant closure\n                  NDC 68382-008-01 in bottles of 100 tablets with child-resistant closure\n                  NDC 68382-008-05 in bottles of 500 tablets\n                  NDC 68382-008-10 in bottles of 1000 tablets\n                  Lamotrigine Tablets USP, 150 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"81\" and other side is plain and are supplied as follows:\n                  NDC 68382-009-14 in bottles of 60 tablets with child-resistant closure\n                  NDC 68382-009-16 in bottles of 90 tablets with child-resistant closure\n                  NDC 68382-009-05 in bottles of 500 tablets\n                  Lamotrigine Tablets USP, 200 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"82\" and other side is plain and are supplied as follows:\n                  NDC 68382-010-14 in bottles of 60 tablets with child-resistant closure\n                  NDC 68382-010-16 in bottles of 90 tablets with child-resistant closure\n                  NDC 68382-010-05 in bottles of 500 tablets\n                  Lamotrigine Tablets USP, 250 mg are white to off-white, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"91\"and other side is plain and are supplied as follows:\n                  NDC 68382-011-14 in bottles of 60 tablets with child-resistant closure\n                  NDC 68382-011-16 in bottles of 90 tablets with child-resistant closure\n                  NDC 68382-011-05 in bottles of 500 tablets\n                  \n                     Lamotrigine Tablets for Oral Suspension, USP \n                  \n                  Lamotrigine Tablets for Oral Suspension USP, 5 mg are white to off-white, round, flat- faced, radial-edged tablets with bisect on one side and plain on other side; one side of the bisect is debossed with \"Z\" and other side is debossed with \"13\" and are supplied as follows:\n                  NDC-68382-108-16 in bottle of 90 tablets with child-resistant closure\n                  NDC-68382-108-01 in bottle of 100 tablets with child-resistant closure\n                  NDC-68382-108-05 in bottle of 500 tablets\n                  Lamotrigine Tablets for Oral Suspension USP, 25 mg are white to off-white, round, flat- faced, radial-edged tablets debossed with logo of \"Z\" and \"12\" on one side and plain on the other side and are supplied as follows:\n                  NDC-68382-109-16 in bottle of 90 tablets with child-resistant closure\n                  NDC-68382-109-01 in bottle of 100 tablets with child-resistant closure\n                  NDC-68382-109-05 in bottle of 500 tablets\n                  \n                     Storage:\n                  \n                  Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature] in a dry place.\n                  Dispense in a tight, light-resistant container as defined in the USP.",
    "adverseReactions": "Hypersensitivity to the drug or its ingredients. ( Boxed Warning , 4 )"
}